Edwards Lifesciences

Forecast & Rating28 analysts currently cover Edwards Lifesciences, with about 71.4% giving a positive rating — meaning they expect the stock to rise. The average price target is $99.96, about 19.3% upside from the current price of $83.82. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 80.7% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Edwards Lifesciences closely still see room for the stock to rise. Data as of Jul 24, 2026; for reference only and not investment advice.